465 results about "Mouse Heart" patented technology

An image guided navigation system for navigating a region of a patient includes an imaging device, a tracking device, a controller, and a display. The imaging device generates images of the region of a patient. The tracking device tracks the location of the instrument in a region of the patient. The controller superimposes an icon representative of the instrument onto the images generated from the imaging device based upon the location of the instrument. The display displays the image with the superimposed instrument. The images and a registration process may be synchronized to a physiological event. The controller may also provide and automatically identify an optimized site to navigate the instrument to.

Systems and methods for providing communications between an external device and first and second leadless pacemakers (LPs) located in a heart are provided. A method includes receiving first and second event messages from the first and second LPs, the first and second event messages received at different points in time at the external device, determining the signal strengths of the first and second event messages, respectively, as received at the external device, adjusting first and second LP discrimination thresholds based on the received signal strengths of the first and second event messages, respectively, and utilizing the first and second LP discrimination thresholds to identify which of the first and second LP transmits subsequent event messages, in order for the external device to independently communicate with the first and second LPs.

The present invention provides methods for screening drugs inhibiting the expression of OSF-2 gene or the production or function of the protein encoded thereby and therapeutic agents for heart failure having such effects. Useful methods for diagnosing heart failure can be provided by monitoring the expression or variation of said gene or the production of the protein encoded thereby. The present invention also provides transgenic animals with forced expression of OSF-2 gene and methods for studying changes in gene expression or protein production or the functions of various genes or proteins with the progress of the pathology of heart failure using them and novel therapeutic agents for heart failure.

The invention relates to a materialized heart 3D model manufacturing method capable of achieving internal and external structures. The method can overcome the defects in the prior art. The method includes the steps that (1) the heart part of a patient is scanned to obtain medical image data to form a DICOM file; (2) the DICOM file obtained in the step (1) is identified through Mimics software and stored to form a computer-identified .mcs file; (3) different data templates are extracted from the software; (4) the templates, with cavity structures or incomplete images or unclear boundaries, obtained in the step (3) are processed to be made clear and complete; (5) a needed template is formed by adding or deleting or separating or combining the templates; (6) a 3D image formed in the step (5) is processed to enable the exterior of the 3D image to be smooth and interior image templates to be complete to form an STL file; (7) data processed in the step (6) are input in a 3D laser printer, and accordingly a heart model is printed. According to the method, heart models with clear and complete structures can be obtained, and the success rate of heart operations can be greatly increased.

Apparatus and associated methodology for monitoring correlatable anatomical electrical and sound signals, such as electrical and audio signals produced by human heart activity, including (a) attaching to a selected, common anatomical site ECG (or other) electrode structure, and a multi-axial sound sensor, and (b) simultaneously collecting from adjacent that site both ECG(or other)-electrical and sound signals, where such sound signals arrive adjacent the site along multiple, angularly intersecting axes.

A system and method for recording and depicting ultrasound images of a moving object are disclosed. In a preferred embodiment, ultrasound images are acquired as the field of view of an ultrasound probe is advanced across the tissues of interest during a resting period between periods of relatively large-scale heart cycle motion. A series of images acquired during a particular resting period may be represented as a three-dimensional volume image, and the comparison of volume images from adjacent cardiac resting periods enables three-dimensional volume image modulation analysis which may be presented for a user as a moving volume image of the objects of interest within the field of view.

A method for treating a subject afflicted with a cardiac disorder, in vivo, comprising (i) producing a solution comprising media conditioned from the culture of cells, in vitro, and (ii) administering the solution of step (i) to the subject, thereby treating the cardiac disorder in the subject. Methods for determining whether an agent stimulates or inhibits myocyte proliferation.

The invention features an optically-controlled biological device that includes a biological component comprising a non-excitable cell expressing a light-gated ion channel protein and capable of forming gap junction channels with a target cell, and an optical stimulation unit.

The invention relates to a surface modification method and application of a porous material. The surface modification method of the porous material comprises the following steps: soaking the porous material in a zwitter-ion reaction solution and fully wetting the porous material; and taking out the wetted porous material and carrying out crosslinking to obtain a zwitter-ion hydrogel modified porous material. The zwitter-ion reaction solution comprises 10-50% of zwitter-ion monomers, 0.01-5% of a crosslinking agent, 0.01-0.5% of an initiator and a solvent. The method is a universal surface modification method; a modification process is simple and convenient; a modified coating can be stable in a complicated biotic environment for a long time, the modified surface has a certain pore structure, therefore, the porous material loaded with a water-soluble and hydrophobic drug can be modified, and the purposes of releasing the drug in a sustained manner and improving the bioavailability of the drug are achieved; and the surface modification method can be used for modifying surfaces of porous metal or alloy, and is applied to repair or replacement of materials such as skin, cardiac valves,bones, cartilages or vascular tissues.

This document discusses, among other things a cardiac lead with first and second electrodes electrically interconnected by back-to-back diodes or another conductivity control device. During sensing of intrinsic electrical heart signals, these electrodes are isolated from each other by the conductivity control device. This reduces noise during sensing. During pacing or defibrillation, these electrodes are electrically connected to each other by the conductivity control device. When used in common as a return path electrode, this avoids unintentional stimulation of the heart at the return path electrode instead of at the stimulating electrode. The electrodes can also share a common conductor from one of the electrodes back to a proximal end of the lead.

The invention includes a zebrafish assay for cardiac response.

The present invention relates to stabilised <99m>Tc radiopharmaceutical compositions, which include both a radioprotectant and one or more antimicrobial preservative(s), and hence have an extended lifetime of use. The radioprotectant is ascorbic acid, para-aminobenzoic acid, gentisic acid or a salt thereof with a biocompatible cation, and the antimicrobial preservative is one or more compound from the paraben series of preservatives. The invention is particularly useful for cationic, lipophilic <99m>Tc heart imaging agents such as Myoview(TM).

The present invention provides peptide-based peroxidase inhibitors having the formula AA₁-AA₂-AA₃, wherein AA₁ is a positively charged, negatively charged or neutral amino acid, AA₂ is a redox active amino acid, and AA₃ is an amino acid possessing a reducing potential such that AA₃ is capable of undergoing a redox reaction with a radical of amino acid AA₂ or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.

Described embodiments are directed toward prosthetic valve leaflets of particular configurations that control bending character. In embodiments provided herein, a valve leaflet is provided with a planar zone that is bounded at a planar zone base by a straight line, wherein the leaflet is operable to bend along a base of the planar zone.

A method of analyzing the electrocardiogram ("ECG") using a set of vectors mathematically derived from the heart vector. The entire ECG waveform of one representative heartbeat is analyzed as a time series of vectors taken at selected time intervals. The vector set consists of the heart vector, the vector of deviation, vector of abnormality, delta vector, the delta vector deviation, and the delta vector abnormality. The analysis system can be applied to two or any greater number of ECG leads represented on planar axes, orthogonal spatial axes, or four or more axes in multidimensional space. The normal range of the ECG in this method is delineated by an adaptive multi-dimensional polyhedron in space to which the unknown ECG is compared. This is accomplished by utilizing a computer platform and the software program to support the required mathematical calculations.

Cell transplantation for constructing biological heart pacemaker is used embryo source dry/ancestral cell and adult mesogalia dry cell as cell sources. The process is carried out by oriented differentiation inducing for heart pacemaker cell by embryo source multifunctional dry cell, bone marrow adhering to obtain primary culture cell, clone culturing to obtain purifying system by diluting, applying paracrine factor endothelin-1 or nervous adjusting protein-1, extracellular matrix laminated adherent protein and fiber connecting protein etc. substrate glue, trans-dyeing pacemaker gene HCN4, and in-vitro inducing embryo source multifunctional dry cell. It is various and non-immunogenicity. It can be used to treat sick sinus syndrome.

The present invention relates to neukinase, a downstream protein kinase in the neuregulin signaling pathway. In certain aspects, the present invention provides isolated neukinase-encoding nucleic acids, neukinase polypeptides, oligonucleotides that hybridize to neukinase nucleic acids, and expression vectors containing neukinase-encoding sequences. The present invention further provides isolated host cells, antibodies, transgenic non-human animals, compositions, and kits relating to neukinase. In other aspects, the present invention further provides methods of identifying predisposition to cardiac dysfunction, methods of detecting the presence of neukinase, neukinase nucleic acid, methods of screening for agents which affect neukinase activity, and methods of modulating neukinase activity.

The present invention provides methods of identifying an incidence of ischemia in mammalian tissue, particularly mammalian heart tissue. Further, a method of reducing apoptosis in mammalian tissue, preferably heat tissue, is provided. These methods involve measuring and comparing the gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A and correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5a is higher than proliferating eIF-5A. In the method of reducing apoptosis in mammalian tissue, there is provided an agent that inhibits expression of apoptosis-specific eIF-5A. Preferred agents are antisense oligonucleotides to human apoptosis-specific eIF-5A.

A shotgun metabolomics approach using MALDI-tandem mass spectrometry was developed for the rapid analysis of cellular metabolites. Through the use of neutral organic solvents to inactivate endogenous enzyme activities (i.e., methanol/chloroform/H₂O extraction), multiplexed extraction conditions and combinatorial alterations in matrix stereoelectronic composition and analyte interactions, multiple suites of metabolites were directly ionized and quantitated directly from biologic extracts without the need for prior chromatographic separation. Through combinatorial alterations in 9-aminoacridine charge, aromaticity and stacking, a set of multiplexed conditions was developed that allowed identification of many hundreds of peaks corresponding to metabolites from mouse heart extracts. Identification of metabolite peaks was based on mass accuracy and isomeric species were assigned based on diagnostic fragment ions present during tandem mass spectrometry for many of the identified metabolite peaks.

A novel population of multipotent cardiac precursor (MCP) cells derived from human blastocysts derived stem cells is disclosed, methods for the preparation thereof and use of the cells for in vitro testing. Basement cells derived from hBS cells are also disclosed and method for the preparation of MCP cells from basement cells. The MCP cells have the following characteristics

• • i) at least 1% of the cells exhibit no antigen expression of one or more markers for undifferentiated cell, the marker being selected from the group consisting of SSEA-3, SSEA-4, TRA-1-60, TRA-1-81 and Oct-4,
  • ii) at least 1% of the cells exhibit no protein expression of one or more of a neural marker including nestin or GFAP
  • iii) at least 1% of the cells exhibit protein and/or gene expression of one or more of a mesodermal marker including brachyury, vimentin or desmin
  • iv) at least 1% of the cells exhibit protein and/or gene expression of Flk-1 (KDR).

Furthermore, the MCP cells have a characteristic morphology. They grow as clusters of small, round and phase-bright cells; individual cells are 5-20 μm in diameter and each cluster is composed of 2-500 cells. They form clusters of round or elongated shape, that appear as loosely adherent cell clumps that as illustrated in FIG. 2 panel a, b and c. Furthermore, they have a relatively high nucleus-to-cytoplasma ratio, e.g. 1:2-1:64 of the total volume of the cell and/or appear as balloons on a string, as illustrated in FIG. 18, schematic sketch. Moreover, the MCP cells are non-contracting.